High-dose ascorbate

Phase 2Small molecule

High-dose ascorbate is one of 75 small molecule programs targeting Myelodysplastic Syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myelodysplastic SyndromeActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

Myelodysplastic SyndromePhase 2

Active, not recruiting

Acute Myeloid LeukemiaPhase 1

Active, not recruiting

Competition

Competitive Landscape

804 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Peony

Takeda

Phase 3

6 2

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

1 3

Alkeran

AApotex Inc.

Phase 3

7 4

Decadron

AAspen Global Incorporated

Phase 3

5 5

Tabloid

Akero Therapeutics

Phase 3

2 6

Campath

GGenzyme, a Sanofi Company

Phase 3

—7

APG-2575

Ascentage Pharma Group Inc.

Phase 3

1 8

Histamine Dihydrochloride

MMaxim Pharmaceuticals

Phase 3

1 9

HMPL-306

HHutchmed

Phase 3

1 10

ALL-Trans Retinoid Acid

UUniversity of Ulm

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 2Recruiting

Myelodysplastic Syndrome

NCT07283900

Q4 2029

Phase 1Not yet recruiting

Acute Myeloid Leukemia

NCT07177079

Clinical

Trials by Indication[1]

Myelodysplastic Syndrome1 trial

Ascorbate in Myelodysplastic Syndrome

Recruiting·PPrajwal Dhakal·Phase 2·NCT07283900·38 enrolled

Acute Myeloid Leukemia1 trial

High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)

Not yet recruiting·KKittika Poonsombudlert·Phase 1·NCT07177079·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for High-dose ascorbate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — High-dose ascorbate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for High-dose ascorbate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Prajwal Dhakal company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPrajwal Dhakal

High-dose ascorbate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Q4 2029

Trials by Indication[1]

Myelodysplastic Syndrome1 trial

Acute Myeloid Leukemia1 trial

References

Drug Info

Quick Facts

Related News